Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial.

PubWeight™: 4.09‹?› | Rank: Top 1%

🔗 View Article (PMC 3486644)

Published in JAMA on May 11, 2011


Samer S Najjar1, Sunil V Rao, Chiara Melloni, Subha V Raman, Thomas J Povsic, Laura Melton, Gregory W Barsness, Kristi Prather, John F Heitner, Rakhi Kilaru, Luis Gruberg, Vic Hasselblad, Adam B Greenbaum, Manesh Patel, Raymond J Kim, Mark Talan, Luigi Ferrucci, Dan L Longo, Edward G Lakatta, Robert A Harrington, REVEAL Investigators

Author Affiliations

1: Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA.

Associated clinical trials:

REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction | NCT00378352

Erythropoietin Effect on ischemic_ Reperfusion Injury in Cronary Artery Bypass Graft Surgery | NCT02984111

Articles citing this

Ischemia and reperfusion--from mechanism to translation. Nat Med (2011) 6.64

Endothelial nitric oxide synthase in red blood cells: key to a new erythrocrine function? Redox Biol (2014) 2.18

Management of aneurysmal subarachnoid hemorrhage: State of the art and future perspectives. Surg Neurol Int (2017) 1.45

Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc Diabetol (2012) 1.21

Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI). Eur Heart J (2014) 1.11

Myocardial perfusion and contraction in acute ischemia and chronic ischemic heart disease. J Mol Cell Cardiol (2011) 1.08

Erythropoietin in the intensive care unit: beyond treatment of anemia. Ann Intensive Care (2011) 1.03

The effect of erythropoietin on normal and neoplastic cells. Biologics (2012) 0.98

Myocardial salvage in acute myocardial infarction--challenges in clinical translation. J Mol Cell Cardiol (2011) 0.98

Erythropoietin: new directions for the nervous system. Int J Mol Sci (2012) 0.95

Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial. Clin J Am Soc Nephrol (2012) 0.94

Impact of erythropoietin on intensive care unit patients. Transfus Med Hemother (2013) 0.91

Erythropoietin action in stress response, tissue maintenance and metabolism. Int J Mol Sci (2014) 0.91

The anti-oxidative role of micro-vesicles derived from human Wharton-Jelly mesenchymal stromal cells through NOX2/gp91(phox) suppression in alleviating renal ischemia-reperfusion injury in rats. PLoS One (2014) 0.90

Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety. Crit Care (2013) 0.89

Hemoglobin variability with epoetin beta and continuous erythropoietin receptor activator in patients on peritoneal dialysis. Perit Dial Int (2011) 0.87

Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis. Open Heart (2014) 0.87

Cardioprotection and pharmacological therapies in acute myocardial infarction: Challenges in the current era. World J Cardiol (2014) 0.87

Left ventricular functional assessment in murine models of ischemic and dilated cardiomyopathy using [18 F]FDG-PET: comparison with cardiac MRI and monitoring erythropoietin therapy. EJNMMI Res (2012) 0.85

Stimulatory effects of the flavanol (-)-epicatechin on cardiac angiogenesis: additive effects with exercise. J Cardiovasc Pharmacol (2012) 0.84

Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair. Circ Res (2013) 0.84

Human erythropoietin gene delivery for cardiac remodeling of myocardial infarction in rats. J Control Release (2013) 0.82

EPC mobilization after erythropoietin treatment in acute ST-elevation myocardial infarction: the REVEAL EPC substudy. J Thromb Thrombolysis (2013) 0.81

Adjuvant cardioprotection in cardiac surgery: update. Biomed Res Int (2014) 0.81

Up-regulation of microRNA-21 mediates isoflurane-induced protection of cardiomyocytes. Anesthesiology (2015) 0.81

Concise Review: Endothelial Progenitor Cells in Regenerative Medicine: Applications and Challenges. Stem Cells Transl Med (2016) 0.80

Effects of recombinant human erythropoietin on resistance artery endothelial function in stage 4 chronic kidney disease. J Am Heart Assoc (2013) 0.80

Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care. Crit Care (2012) 0.80

Molecular mechanisms of ischemic preconditioning in the kidney. Am J Physiol Renal Physiol (2015) 0.80

Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues. PLoS One (2015) 0.79

The influence of the pleiotropic action of erythropoietin and its derivatives on nephroprotection. Med Sci Monit (2013) 0.79

The mitochondria-targeted antioxidants and remote kidney preconditioning ameliorate brain damage through kidney-to-brain cross-talk. PLoS One (2012) 0.79

Did clinical trials in which erythropoietin failed to reduce acute myocardial infarct size miss a narrow therapeutic window? PLoS One (2012) 0.78

Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review. Eur J Clin Pharmacol (2011) 0.78

Erythropoietin in the critically ill: do we ask the right questions? Crit Care (2012) 0.78

Baseline Hemoglobin Levels Associated with One-Year Mortality in ST-Segment Elevation Myocardial Infarction Patients. Acta Cardiol Sin (2016) 0.77

Endothelial Progenitor Cell Levels Predict Future Physical Function: An Exploratory Analysis From the VA Enhanced Fitness Study. J Gerontol A Biol Sci Med Sci (2015) 0.77

Evaluation of agents to reduce infarct size: it can be quite REVEALing. JAMA (2011) 0.77

Image-guided therapies for myocardial repair: concepts and practical implementation. Eur Heart J Cardiovasc Imaging (2013) 0.77

Regeneration in the nervous system with erythropoietin. Front Biosci (Landmark Ed) (2016) 0.76

Signaling Pathways in Cardiac Myocyte Apoptosis. Biomed Res Int (2016) 0.76

Erythropoietin and organ protection: lessons from negative clinical trials. Crit Care (2014) 0.75

Strategy to Prime the Host and Cells to Augment Therapeutic Efficacy of Progenitor Cells for Patients with Myocardial Infarction. Front Cardiovasc Med (2016) 0.75

Red cell distribution width in anemic patients undergoing transcatheter aortic valve implantation. World J Cardiol (2016) 0.75

SOCS3: A novel therapeutic target for cardioprotection. JAKSTAT (2012) 0.75

The Systematic Evaluation of Identifying the Infarct Related Artery Utilizing Cardiac Magnetic Resonance in Patients Presenting with ST-Elevation Myocardial Infarction. PLoS One (2017) 0.75

Erythropoietin in patients with ST-segment elevation myocardial infarction. JAMA (2011) 0.75

Erythropoietin in patients with ST-segment elevation myocardial infarction. JAMA (2011) 0.75

Anemia and Acute Coronary Syndrome: Time for Intervention Studies. J Am Heart Assoc (2016) 0.75

Reducing infarct size with EPO in patients with ST-segment elevation myocardial infarction. Am J Kidney Dis (2011) 0.75

Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy. Curr Neurovasc Res (2016) 0.75

A sustained-release drug-delivery system of synthetic prostacyclin agonist, ONO-1301SR: a new reagent to enhance cardiac tissue salvage and/or regeneration in the damaged heart. Heart Fail Rev (2015) 0.75

Erythropoietin for the treatment of subarachnoid hemorrhage: A feasible ingredient for a successful medical recipe. Mol Med (2015) 0.75

Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial. BMC Cardiovasc Disord (2017) 0.75

Articles cited by this

Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med (2006) 17.55

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med (1998) 11.58

Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation (1999) 11.04

Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation (1990) 9.74

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA (2008) 8.20

Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke (2009) 5.28

2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2008) 3.70

Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. N Engl J Med (1996) 3.32

Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation (2003) 2.68

Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation (2008) 2.62

Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A (1994) 2.61

A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J (2010) 2.52

A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest (2003) 2.32

Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A (2003) 2.28

Erythropoietin regulates endothelial progenitor cells. Blood (2003) 2.18

Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. The Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2). N Engl J Med (1993) 1.81

Myocardial infarct expansion, infarct extension, and reinfarction: pathophysiologic concepts. Prog Cardiovasc Dis (1987) 1.75

Regional cardiac dilatation after acute myocardial infarction: recognition by two-dimensional echocardiography. N Engl J Med (1979) 1.71

Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J (2004) 1.67

Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A (2003) 1.64

The cardiovascular effects of erythropoietin. Cardiovasc Res (2003) 1.59

Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol (2006) 1.42

Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun (2003) 1.31

A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther (2006) 1.28

Angiogenesis and plasticity: role of erythropoietin in vascular systems. J Hematother Stem Cell Res (2002) 1.21

Comparison of analytic models for estimating the effect of clinical factors on the cost of coronary artery bypass graft surgery. J Clin Epidemiol (1993) 1.14

Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc Drugs Ther (2005) 1.05

Age-related differences in postinfarct left ventricular rupture and remodeling. Am J Physiol Heart Circ Physiol (2008) 1.05

Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv (2010) 1.04

Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. Am Heart J (2010) 1.00

Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am J Cardiol (2009) 0.97

High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study. Int J Cardiol (2009) 0.96

Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. Am Heart J (2010) 0.94

Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. Int J Cardiol (2007) 0.93

Lack of acute cardioprotective effect from preischaemic erythropoietin administration in a porcine coronary occlusion model. Clin Physiol Funct Imaging (2005) 0.91

Myocardial infarct expansion: recognition, significance and pathology. Am J Cardiol (1991) 0.91

Pharmacologic reperfusion strategies for the treatment of ST-segment elevation myocardial infarction. Rev Cardiovasc Med (2003) 0.83

Articles by these authors

A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science (2007) 37.88

Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07

Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35

Resveratrol improves health and survival of mice on a high-calorie diet. Nature (2006) 20.91

Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66

Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03

New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89

Gait speed and survival in older adults. JAMA (2011) 15.01

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25

Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci (2004) 12.46

Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44

Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86

Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet (2010) 8.74

Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49

Phenotype of frailty: characterization in the women's health and aging studies. J Gerontol A Biol Sci Med Sci (2006) 8.00

Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83

Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81

ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. J Am Coll Cardiol (2006) 7.77

Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48

Interventions used in disease management programmes for patients with chronic illness-which ones work? Meta-analysis of published reports. BMJ (2002) 6.98

Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation (2005) 6.89

Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc (2006) 6.81

Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66

Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36

Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA (2005) 6.10

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02

Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA (2005) 5.93

Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood (2004) 5.86

Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet (2009) 5.81

Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA (2006) 5.78

Red blood cell transfusion: a clinical practice guideline from the AABB*. Ann Intern Med (2012) 5.77

Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol (1985) (2003) 5.73

Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson (2008) 5.65

New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation (2009) 5.49

Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet (2003) 5.33

Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med (2010) 5.20

Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med (2009) 5.19

Data Sharing. N Engl J Med (2016) 5.12

Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04

Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature (2012) 5.00

Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation (2002) 4.99

Frailty: an emerging research and clinical paradigm--issues and controversies. J Gerontol A Biol Sci Med Sci (2007) 4.98

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA (2013) 4.85

Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81

A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet (2008) 4.75

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA (2003) 4.74

Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73

GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71

Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet (2008) 4.69

ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation (2007) 4.66

beta-Adrenergic stimulation modulates ryanodine receptor Ca(2+) release during diastolic depolarization to accelerate pacemaker activity in rabbit sinoatrial nodal cells. Circ Res (2002) 4.66

Hearing loss and incident dementia. Arch Neurol (2011) 4.65

Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J (2005) 4.62

Accelerated longitudinal decline of aerobic capacity in healthy older adults. Circulation (2005) 4.61

PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med (2004) 4.50

A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37

Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet (2009) 4.28

Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA (2004) 4.27

Hearing loss and cognitive decline in older adults. JAMA Intern Med (2013) 4.25

Hearing loss prevalence in the United States. Arch Intern Med (2011) 4.22

Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16

The origins of age-related proinflammatory state. Blood (2004) 4.15

Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging. J Am Coll Cardiol (2006) 4.10

Superoxide flashes in single mitochondria. Cell (2008) 4.08

Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07

Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA (2011) 3.97

Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci (2004) 3.96

Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLoS Med (2011) 3.94

T2 quantification for improved detection of myocardial edema. J Cardiovasc Magn Reson (2009) 3.90

Improving patient care. The patient centered medical home. A Systematic Review. Ann Intern Med (2012) 3.90

Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson (2013) 3.87

Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA (2009) 3.83

Direct T2 quantification of myocardial edema in acute ischemic injury. JACC Cardiovasc Imaging (2011) 3.77

Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes (2008) 3.76

Genetic loci influencing kidney function and chronic kidney disease. Nat Genet (2010) 3.75

Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res (2011) 3.72

Conversion of cardiovascular conference abstracts to publications. Circulation (2012) 3.71

Red blood cell distribution width and the risk of death in middle-aged and older adults. Arch Intern Med (2009) 3.71

Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68

Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry (2010) 3.64

Hearing loss prevalence and risk factors among older adults in the United States. J Gerontol A Biol Sci Med Sci (2011) 3.63

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet (2004) 3.57

Arterial aging: is it an immutable cardiovascular risk factor? Hypertension (2005) 3.55

Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol (2009) 3.54